Author

K. Park

Observed name: K Park

Institutions: The University of Texas MD Anderson Cancer Center, Samsung Medical Center, Sungkyunkwan University

Observed institutions: The University of Texas MD Anderson Cancer Center, Yonsei University, Institut Gustave Roussy, Samsung Medical Center, University of Chicago Medical Center, Yonsei University Health System, Sungkyunkwan University

OpenAlex ID: A5111096321

Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans

2007 · JH Choi, MG Lee, et al. · Clinical Pharmacology & Therapeutics · 132

1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

2020 · M. Reck, A. Spira, et al. · Annals of Oncology · 21

MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation

2021 · M. Reck, A. Spira, et al. · Journal of Thoracic Oncology · 12

OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

2022 · M. Reck, F. Barlesi, et al. · Journal of Thoracic Oncology · 6

JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC)

2017 · M. Reck, C.-H. Yang, et al. · Annals of Oncology · 6

MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC

2024 · J.W. Goldman, B.C. Cho, et al. · Journal of Thoracic Oncology · 4

1212P Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases

2021 · J.Y.C-H. Yang, M. Schuler, et al. · Annals of Oncology · 3

MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations

2021 · J. Chih-Hsin Yang, M. Schuler, et al. · Journal of Thoracic Oncology · 2

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

2020 · J.C-H. Yang, M. Schuler, et al. · Annals of Oncology · 1

443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes

2015 · K. Park, W. Li, et al. · Annals of Oncology · 1

3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes

2015 · G.D. Goss, E. Felip, et al. · European Journal of Cancer · 1

Importance of HPV Involvement and FOXP3+ T-Cell Status as Prognostic Factors in Tonsilar Squamous Cell Carcinoma

2012 · K. Park, K.J. Cho, et al. · Annals of Oncology · 1

754 Joint Association of Plasma 1, 25-dihydroxyvitamin D3 and Igfbp-3 Levels and Vdr Fok1 Polymorphism With Prostate Cancer Risk in Korean Men

2010 · J.H. Kim, S.W. Lee, et al. · European Urology Supplements · 1

1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations

2020 · J.C-H. Yang, M. Schuler, et al. · Annals of Oncology

Afatinib (A) Plus Paclitaxel (P) Following Progression on a Monotherapy in Patients (PTS) with Metastatic Non–Small-Cell Lung Cancer (NSCLC) Who Previously Benefited From Erlotinib (E)/Gefitinib (G): a Global Randomised Phase Iii Trial–Lux-Lung 5 (LL5)

2015 · M. Schuler, J.C.-H. Yang, et al. · Annals of Oncology

Attention Study: Asian Trial of Tivantinib Plus Erlotinib Versus Erlotinib for NSCLC without EGFR Mutation; a Phase 3 Trial with a Personalized Dose Setting Based on Pretreatment Test for CYP2C19 Polymorphism

2012 · K. Park, C.-M. Tsai, et al. · Annals of Oncology

Works count: 16

Citation count: 191

H-index: 5

I10-index: 3